
SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month’s news that Bristol-Myers Squibb plans to buy Celgene in a $74 billion deal.
One of those partners is BeiGene, among the buzziest companies in China’s rising biotech sector and one that could feel ripple effects.
What is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports